Please assess the completion status of the following clinical trial:

Trial Title: N-Acetyl Glucosamine as Therapeutic Intervention for Coronavirus Disease-19 (COVID-19)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥18 years old~* Treated with N-acetyl glucosamine (NAG) as first-line treatment~* Present with coronavirus disease 2019 (COVID-19) symptoms (including but not limited to fever, cough, shortness of breath, sore throat, nasal congestion, malaise, headache, muscle pain, loss of taste and/or smell, diarrhea, and vomiting)~* Clinically diagnosed with COVID-19 by reverse transcription polymerase chain reaction (RT-PCR)~* No intubation prior to hospitalization and enrollment in the current study.~Exclusion Criteria:~* \<18 years old upon admission~* Allergy to NAG~* Allergy to shellfish~* Currently taking warfarin~* Currently pregnant or lactating

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- N-Acetyl Glucosamine (Type: EXPERIMENTAL): All patients in the treatment arm of the study were treated with N-Acetyl Glucosamine, a potential therapy for Coronavirus Disease-19 (COVID-19).
- Control (Type: PLACEBO_COMPARATOR): All patients in the comparator arm were admitted to the same hospital with COVID-19 but did not receive N-Acetyl Glucosamine treatment. All these patients were identified retrospectively.

Based on this trial design, predict the completion outcome and termination type (if applicable).